fecal microbiota therapy fmt in the management of c difficile infection cdi n.
Skip this Video
Loading SlideShow in 5 Seconds..
Fecal Microbiota Therapy (FMT) in the Management of C. difficile Infection (CDI) PowerPoint Presentation
Download Presentation
Fecal Microbiota Therapy (FMT) in the Management of C. difficile Infection (CDI)

Loading in 2 Seconds...

play fullscreen
1 / 43

Fecal Microbiota Therapy (FMT) in the Management of C. difficile Infection (CDI) - PowerPoint PPT Presentation

  • Uploaded on

Freston Symposium. Fecal Microbiota Therapy (FMT) in the Management of C. difficile Infection (CDI). Lawrence J. Brandt, MD Emeritus Chief, Gastroenterology Montefiore Medical Center Professor of Medicine and Surgery Albert Einstein College of Medicine. Conflicts of Interest.

I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
Download Presentation

PowerPoint Slideshow about 'Fecal Microbiota Therapy (FMT) in the Management of C. difficile Infection (CDI)' - cain-saunders

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.

- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
fecal microbiota therapy fmt in the management of c difficile infection cdi

Freston Symposium

Fecal Microbiota Therapy (FMT) in the Management of C. difficile Infection (CDI)

Lawrence J. Brandt, MDEmeritus Chief, Gastroenterology

Montefiore Medical Center

Professor of Medicine and Surgery

Albert Einstein College of Medicine

conflicts of interest
Conflicts of Interest

 Cipac: Advisory Board


Incidence and Impact of C. difficile

~ 500,000 cases~ $5 billion in excess costs~ 30,000 deaths annually

Campbell et al. Infect Control Hosp Epidemiol. 2009:30:523-33 Dubberke et al. Emerg Infect Dis. 2008;14:1031-8

Dubberke et al. Clin Infect Dis. 2008;46:497-504 Elixhauser et al. HCUP Statistical Brief #50. 2008

acg rx guidelines for cdi 2013
ACG Rx Guidelines for CDI, 2013

Mild-moderateMZ (500 mg potid) x 10 days ♦ Strong recommend, high qualevid

SevereVanco (125 mg poqid) x 10 days ♦ Cond recommend, mod qualevidif NRVanco (500 mg poqid) plus MZ (500 mg IV tid) ♦ Strong recommend, mod qualevid

ComplicatedVancopo (125-500 mg qid) and pr (500 mg in 500 mL qid) plus MZ (500 mg IV tid) if ileus, toxic colitis, distention♦ Strong recommend, low qualevidconsider surgRx if: BP (pressors); sepsis, MOF; MS change; WBC≥50 K, lactate ≥5; no improvement (5d) ♦ Strong recommend, mod qualevid

Am J Gastroenterol, 2013

fidaxomicin vs vanco
Fidaxomicin vs Vanco

200mg BID x 10 d

125mg QID x 10 d


Louie TJ et al. N Engl J Med 2011; 364:422-431

fidaxomicin is superior to vanco for 1 st cdi recurrence
Fidaxomicin is superior to Vanco for 1st CDI recurrence

36% (22/62) recurrence

20% (13/66)recurrence

Cornely, OA et al. CID 2012:55 (Suppl 2); 154-61

rifaximin chaser for recurrent cdi
Rifaximin“chaser” for Recurrent CDI



Standard therapy x 10-14 days (MZ , 82%; Vanco,18%)

followed by:

Placebo or Rifaximin (400 mg tid x 20 days)

Garey et al. J Antimicrob Chemother 2011

antibody and vaccine rx
Antibody and Vaccine Rx

Antibodies  RDBPC study of fully human monoclonal antibodies against C. difficile toxins A and B

♦administered as a single infusion (10mg/kg)

♦200 patients, receiving abx for active CDI

♦primary outcome: recurrence w/in 84 days

- antibodies: 7%, placebo: 25%- pts with BI/NAP1/027: 8% vs 32%

- pts with prior recurrence: 7% vs 38%

Vaccines  Sanofi announced (Aug 2013) starting late-stage trials (15,000 people) testing C. difficile vaccine

Lowy I et al. N Engl J Med 2010; 362:197-205

non toxigenic c difficile ntcd strain vp 20261
Non-toxigenicC. difficile (NTCD) Strain VP 20261*

Phase II trial (ViroPharma, Inc)

  • CDI patients on oral vancomycin
  • Placebo (n=43)
  • or NTCD (n=125)

- 104 x 7 days (n=41)

- 107 x 7 days (n=43)

- 107 x 14 days (n=41)

2% CDI recurrence rate in colonized pts



recurrent c difficile infection
Recurrent C.difficile Infection

 15-20% of patients relapse re-infection post-C. difficile IBS

 2nd recurrence: 30-45%; 3rd recurrence:45-60%

 Rx failure before 2003 <10%; after 2003 ~20%

 Relapses can continue for years

 No universal Rx algorithm

 Rxrecommendations are not evidence-based

recurrent c difficile infection why do we get it
Recurrent C.difficile Infection Why Do We Get It?

Impaired host-response

Altered intestinal microbiome




Spor A, Koren O, Ley R. Nature Reviews Microbiology, 2011

decreased diversity of the fecal microbiome in recurrent c difficile
Decreased Diversity of the Fecal Microbiome in Recurrent C.difficile

 Patients with recurrent C.difficile have decreased phylogenetic richness

 Bacteroidetes and Firmicutes are reduced in patients with recurrent C.difficilenot in patients with just one episode of C.difficile infection

Chang JY, et al. J Infect Dis 2008:197;435-8

Mouse Model for C. difficile-Mediated Dysbiosis... and Successful FMT


Antibiotic perturbation (clinda x 7d)

Expansion of microbiota

C. difficile(027/B1)

Persistent dysbiosis

Transient dysbiosis

Disrupted dysbiosis↓shedding C. difficile

Simplified microbiota↑pro-inflammatory genes↓ butyrate, acetate↑succinate


BacterioRx (6 spp) or FMT

or FMT

Modified from: Lawley TD et al.. PLoS Pathog (2012); 8: e1002995.

acg rx guidelines for cdi 20131
ACG Rx Guidelines for CDI, 2013

Recurrent CDI1st: Can use same Rx as for initial episode; if severe, use Vanco 2nd: Pulsed vanco regimen ♦ Cond recommend, low qualevid

3rd: Pulsed-tapered Vanco; (no comparative data) - 125 mg daily pulsed Q3D for 10 doses -qidtid bid qdregimen

-qid interval dosing (q2d, q3d, q4d) Consider FMT. ♦ Cond recommend, low qualevid

Intravenous immune globulin (IVIG) may be helpful in hypo-gammaglobulinemic pts ♦ Strong recommend, low qualevid

Am J Gastroenterol, 2013

fecal microbiota transplantation fmt
Fecal Microbiota Transplantation (FMT)

 Definition: Instillation of stool from a healthy person into a sick person to cure a certain disease

 Rationale: A perturbed imbalance in our intestinal microbiota (dysbiosis) is associated with or causes disease and can be corrected by re-introduction of donor feces

rationale for fmt in recurrent cdi
Rationale for FMT in Recurrent CDI

Avoid prolonged, repeated courses of antibiotics

Re-establish normal diversity of the intestinal microbiome, thus restoring “colonization resistance”

early history of fmt
Early History of FMT

4th century: Ge Hong described use of human fecal suspension by mouth for food poisoning or severe diarrhea “Zghou Hou Bei Ji Fang” (Handy Therapy for Emergencies)

16th century: Li Shizhen detailed prescriptions of fermented fecal solution, fresh fecal suspension, dry feces or infant feces for abdominal diseases with diarrhea, abdominal pain, fever, vomiting and constipation; “yellow dragon soup”“Ben Cao Gang Mu ” (Compendium of Materia Medica )

17th century: veterinary medicine:transfaunation (transfer of cecal contents or fresh feces) from healthy horses to treat horses with chronic diarrhea

rumen transfaunationis used to refaunate cows that have been off-feed because of mastitis or other illness

later history of fmt
Later History of FMT

 1958: Eismann et al.  4 pts with pseudomembranous colitis (Micrococcus pyogenes)Rxd with FMT enema

 1983: Schwann, et al.  CDI Rxd with FMT enema

 Other methods of FMT 1991: NG tube (Aas, Gessert, Bakken)1998: gastroscopy and colonoscopy (Lund-TØnnesen) 2000: colonoscopy (Persky, Brandt) 2010: self-administered enemas (Silverman, Davis, Pillai)

protocol for fmt in recurrent cdi
Protocol for FMT in Recurrent CDI

Choose donor  any healthy person universal donor

Donor exclusions  antibiotic use within 3 months  diarrhea, constipation, IBS, IBD, colorectal CA, immunocompromise, anti-neoplastic drugs, high-risk behaviors: MSMP, recent body piercing or tattoo  other: diabetes, obesity, atopy, ASCVD... ? psychologic or mood disorder, neurologic disease...

Donor testing  stool: culture (incl Listeria, Vibrios), O & P, C. difficile, H. pylori Ag, Giardia Ag, cryptosporidium, isospora, norovirus  blood: hepatitis A, B, C, syphilis, HIV 1, 2


protocol for fmt in recurrent cdi1
Protocol for FMT in Recurrent CDI

Recipient  D/C antibiotics 2-3 days before procedure? Large-volume colonoscopy prep the evening before procedure

 Loperamide before procedure?

Donor Gentle laxative (e.g., MOM) the night before the procedure? Freshly passed stool is used within 6 hours Stool need not be refrigerated

protocol for colonoscopic fmt in recurrent cdi
Protocol for Colonoscopic FMT in Recurrent CDI

Stool Transplant Donor stool → suspension with non-bacteriostatic saline mix by hand mix by blender Filtered through gauze into canister  Use of a hood (stool is a level 2 biohazard)  60 cc catheter-tip syringe connected to “suction” tubing Volume of ~300cc instilled into ascending colon


Meta-analysis of Clinical Resolution Rates (11of 2709 reports, 273 patients)

Resolution 90% overall lower: 91% upper: 82% No AEs

Kassam et al . AM J Gastroenterol, 2013

fmt for treatment of cdi a systematic review
FMT for Treatment of CDI: A Systematic Review

Site of FMT

# of Pts

Dose of FMT(mean g/mls)

Success Rate (%)

Stomach 109 25/68 81

Duod/Jejunum 97 63/252 86

Cecum/Asc Colon 214 93/281 93

Distal Colon 116 58/272 84

Cammarota G, Ianiro G, Gasbarrini, A. J Clin Gastroenterol, 2014

nasoduodenal fmt for recurrent cdi a rct
Nasoduodenal FMT for Recurrent CDI: a RCT

Study terminated by DSMB AEs: transient cramping, belchingSAEs: none

van Nood E , Vrieze A , Nieuwdorp M et al. N Engl J Med 2013;368:407–15

follow up survey 77 patients 3 months after fmt
Follow-up Survey 77 patients > 3 months after FMT

Mean duration of illness: 11 monthsSymptomatic response after FMT mean of 6 days < 3 days in 74%

 Primary cure rate: 91 % Secondary cure rate: 98.7% 97% of patients would have another FMT for recurrent CDI and 58.3 % would choose FMT as their preferred Rx

All late recurrences occurred in setting of subsequent unrelated antibiotics

Brandt LJ, et al. Am J Gastroenterol, 2012

cure rates and aes in 146 patients 65 years of age
Cure Rates and AEsin 146 Patients > 65 years of Age

Agrawal M, Aroniadis O, Brandt L, et al, DDW, 2014

how do patients feel about fmt
HowDo Patients Feel About FMT?

 Hypothetical case scenarios given to clinic attendees (n=192) efficacy data alone (Floral Reconstitution) (85%)  awareness of fecal nature of FR (81%)  FMT chosen if by pill (90%) or if MD recommended (94%)

 FMT issues found most unappealing need to handle stool (65%) receiving FMT by NGT (75%) women: all aspects of FMT unappealing, “gross” (odor, handling stool) men: concerned with safety issues no signif diff in age or education level older patients: FMT less unappealing

Zipursky, et al. Clin Infect Dis, 2013

how do physicians feel about fmt
HowDo Physicians Feel About FMT?

 2010 (Kelly et al): 73 physicians 10% had performed FMT or knew a colleague who had

 48% willing to try FMT

34% unwilling to try FMT

 2013 (Sofi et al): 118 physicians (85GE, 32ID) 86% willing to do FMT 9% unwilling to do FMT need for published Guidelines concerns for safety

Kelly, ACG meeting 2010; Sofi, Am J Gastroenterol 2013

fda regulations
FDA Regulations

Early 2013. Fecal microbiota falls within the definition of a biologic product and a drug. Since FMT has not yet been approved by the FDA for any specific clinical indication, it constitutes an investigational agent and requires an Investigational New Drug application (IND) from Center for Biologics Evaluation and Research(CBER) . 

May, 2013. Public workshop on FMT

July, 2013. FDA intends to exercise “enforcement discretion” regarding IND requirements for the use of FMT to treat C. difficile infection not responding to standard therapies…provided that the treating physician obtains [appropriate] adequate informed consent . Informed consent should include, at a minimum, a statement that the use of FMT products to treat C. difficile is investigational and a discussion of its potential risks.

fmt the next steps
FMT…the next steps

A. Frozen fecal material from a universal donor*

Donor MaterialNSuccess* Recurrence

Pt-identified donor 10 7/10 (70%) 3/10 (30%)

Std donor, fresh 12 11/12 (92%)

Std donor, frozen 21 19/21 (90%)

Total 43 37/43 (86%) 6/43 (14%)

3/33 (9%)

4 of 6 patients with RCDI had a 2nd FMT (std donor) all cleared their infection final success rate of 41/43 (95%)

B. Synthetic stool (33 bacterial strains) from healthy donor

(Repoopulate) #

2 patients cured of RCDI

C. 3 strains of Bacteroides (ovatus, fragilis, thetaiotaomicron) 

1 patient cured of RCDI

D. Poop pills%: 27 patients took 24-34 pills  all cured of RCDI

# Petrov ,, et al. Microbiome 2013;  Graham, ACG. 2013

*Hamilton, et al. Am J Gastroenterol 2012;

%Thomas Louie, Univ of Calgary; ID week, 2013


Therapeutic unit of full-spectrum microbiota

Petrof EO, Khoruts A. Gastroenterology 2014


Anatomy of a Robogut

Petrof EO, Khoruts A. Gastroenterology 2014







Fecal Microbial Transplant


Single strain


Ecosystem Effects

Modfied from Olle, B. Nature Biotechnology, 2013

safety and ethical concerns
Safety and Ethical Concerns

Acute infectionsbacterial, viral, parasiticcolonic, systemic

Acute allergic reactions


Long-term concernsis it possible that we are predisposing the recipient to (some, all) of the diseases /conditions that the donor will develop in his/her lifetime?have we created a microbiomic clone of the donor?forhow long will the donor microbiota populate the recipient’s colon?

future areas of investigation
Future Areas of Investigation

 IndicationsCDI:severe, complicated disease? 1st occurrence?other GI diseases: IBD, IBS, constipation  non-GI diseases: diabetes, obesity, Parkinson’s, MS, autism?

 Route and means of administration

 Safety and ethical concerns:  short-term: infections, allergies long-term: diseases of the donor, altered microbiota

 Product development processed stool → spec strains ± bioactive molecules


Use the safest product possiblestool is most problematicstool-derived product from volunteer population is probably safer bioengineered (commercial) product is safest

Monitor results carefullynational registry for all FMT

take home points
Take Home Points

Current guidelines are rational and initial routine care should be concordant with these recommendations

 Fidaxomicin is effective

 FMT has reached a “critical mass” and is likely the most appropriate salvage therapy currently available for multiply recurrent CDI.  More robust (RCTs) data are needed.  Concern for long-term sequelae

 FMT will be replaced by bioengineered product(s)